Biovitrum and Synphora Initiate Phase II Study of Psoriasis Treatment
Biovitrum entered an agreement with Synphora in the autumn of 2006 regarding a new drug candidate (JB991) for the treatment of the skin disease psoriasis and other conditions. A clinical Phase II study of this drug candidate is now underway, and the results are expected to be known during second half of 2007.
The first clinical trial for testing safety has been analyzed, and the positive results are grounds for continued clinical studies. The recently initiated Phase II study involves 25-30 patients. The Phase II trial is a dose-response study and is being conducted at the Akademiska Hospital in Uppsala. The results are expected to be known during second half of 2007.
JB991 is a prostaglandin derivative, i.e. a substance which is based on prostaglandin, a local hormone that naturally occurs in the body and plays an important role for the control of inflammation. JB991 was developed by Synphora and emanates from the company's vast knowledge base and experience in prostaglandin-dependent mechanisms.
Synphora is fully responsible for the studies of JB991 through the completion of Phase IIa. Biovitrum will provide financing for the Phase II study at a amount of SEK 3 million. In exchange for this investment, Biovitrum will have the opportunity, under certain provisions, to acquire the project after Phase IIa, on predetermined terms.
Other news from the department business & finance
